Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes

Citations Over TimeTop 10% of 2011 papers

Abstract

The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign. A more potent analogue, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A. Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidation and structural rearrangement to afford the thiohydantoin 47, a compound with reduced HCV inhibitory activity. However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions containing a dimeric species 48 that exhibited potent antiviral activity. Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, symmetrical, pharmacophore realized most effectively with the stilbene 55, a compound that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.

Related Papers

• → Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia(2015)12 cited
• → Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis(2010)11 cited
• → Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection(2021)5 cited
• → HCV-2a NS5A downregulates viral translation predominantly through domain I(2020)4 cited
• → Resistance-Associated Variants in the NS5A Region of HCV and Methods for the Detection(2016)